<DOC>
	<DOC>NCT00748852</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and CETP activity and mass.</brief_summary>
	<brief_title>Safety Study of JTT-302 in Subjects With Low HDL-C Levels</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Subjects must have successfully completed the 4week treatment period of study AT302U06003 Females who are pregnant or lactating, and females of child bearing potential who are not using an effective method of contraception Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol Subjects who cannot follow the prescription and OTC medication restrictions defined in the protocol Flushots not permitted during the study, including the followup period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>